Moderna says flu vaccine showed promising results in phase three trial, paving path to approval

Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix. 

Previous post American Airlines, Spirit Airlines cut summer profit forecast on higher costs
Next post : Controlled environment agriculture construction company Urban-gro’s stock rallies as it wins cannabis contracts